{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T18:09:04Z","timestamp":1784052544946,"version":"3.55.0"},"reference-count":33,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016018","name":"Universidad El Bosque","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016018","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Yellow fever (YF) remains a major global public health challenge, with recurrent outbreaks in Africa and the Americas despite the long-standing availability of a highly effective vaccine. In recent years, outbreaks in Brazil and Colombia (2024\u20132025) have underscored persistent barriers to achieving optimal vaccination coverage and have highlighted the predominantly reactive nature of many public health responses to YF transmission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To map and synthesize evidence published between 2020 and 2025 on YF immunoprevention and immunomodulation at global, Latin American, and Colombian levels, identifying advances, gaps, and implications for public health policy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A scoping review was conducted following PRISMA-ScR guidelines. Eligible sources included original research, reviews, and official documents addressing vaccination strategies, safety, and immune responses. Publications in English, Spanish, and Portuguese from January 2020 to September 2025 were retrieved from major databases and grey literature sources. Data were tabulated and descriptively synthesized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seventy-eight documents met inclusion criteria. The literature consistently supported the high efficacy of a single 17D vaccine dose, with fractional dosing validated as an emergency strategy in contexts of vaccine shortage. Immunological evidence confirmed strong and durable humoral and cellular responses, consistent with foundational studies conducted prior to 2020. However, important gaps persist, particularly regarding immunogenicity and safety in Latin American populations, older adults, pregnant women, and people living with HIV. In Colombia, universal vaccination campaigns during the 2025 outbreak improved coverage but revealed weaknesses in pharmacovigilance, local research capacity, and sustained prevention strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec005\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The 17D vaccine remains the cornerstone of YF control. However, sustaining elimination goals requires not only maintaining \u226595% vaccination coverage but also strengthening pharmacovigilance systems, generating locally relevant immunological evidence, and transitioning from reactive outbreak responses to more proactive, context-sensitive vaccination strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0352755","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T17:32:28Z","timestamp":1784050348000},"page":"e0352755","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunoprevention and immunomodulation of yellow fever: A scoping review of global and Latin American evidence"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4630-4272","authenticated-orcid":true,"given":"Cl\u00edmaco de Jes\u00fas","family":"P\u00e9rez Molina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flor Elena","family":"Chavarro Bermeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlin Martha Bibiana","family":"P\u00e9rez Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"pone.0352755.ref001","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jcv.2014.08.030","article-title":"Yellow fever","volume":"64","author":"TP Monath","year":"2015","journal-title":"J Clin Virol"},{"issue":"1","key":"pone.0352755.ref002","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S1473-3099(01)00016-0","article-title":"Yellow fever: an update","volume":"1","author":"TP Monath","year":"2001","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"pone.0352755.ref003","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1001\/jama.300.8.960","article-title":"Yellow fever: 100 years of discovery","volume":"300","author":"JE Staples","year":"2008","journal-title":"JAMA"},{"key":"pone.0352755.ref004","author":"World Health Organization"},{"issue":"6405","key":"pone.0352755.ref005","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1126\/science.aau8225","article-title":"The reemergence of yellow fever","volume":"361","author":"ADT Barrett","year":"2018","journal-title":"Science"},{"issue":"75","key":"pone.0352755.ref006","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1098\/rsif.2012.0138","article-title":"Suitability of European climate for Aedes albopictus","volume":"9","author":"C Caminade","year":"2012","journal-title":"J R Soc Interface"},{"issue":"10","key":"pone.0352755.ref007","doi-asserted-by":"crossref","DOI":"10.1590\/0074-02760180278","article-title":"Yellow fever outbreak in Brazil","volume":"113","author":"C Possas","year":"2018","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"pone.0352755.ref008","author":"Pan American Health Organization. Epidemiological alert: Yellow fever in the Americas","year":"2025"},{"key":"pone.0352755.ref009","author":"Instituto Nacional de Salud","year":"2025"},{"key":"pone.0352755.ref010","author":"Ministerio de Salud y Protecci\u00f3n Social. Resoluci\u00f3n 691 de 2025","year":"2025"},{"key":"pone.0352755.ref011","author":"Ministerio de Salud y Protecci\u00f3n Social","year":"2025"},{"key":"pone.0352755.ref012","author":"Pan American Health Organization","year":"2025"},{"issue":"27","key":"pone.0352755.ref013","first-page":"269","article-title":"Vaccines and vaccination against yellow fever. WHO position paper -- June 2013","volume":"88","year":"2013","journal-title":"Wkly Epidemiol Rec"},{"issue":"11","key":"pone.0352755.ref014","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1517\/14712598.8.11.1787","article-title":"Yellow fever vaccine: past, present and future","volume":"8","author":"AH Roukens","year":"2008","journal-title":"Expert Opin Biol Ther"},{"issue":"4","key":"pone.0352755.ref015","doi-asserted-by":"crossref","first-page":"879","DOI":"10.4161\/hv.22982","article-title":"17DD yellow fever vaccine: a dose-response randomized clinical trial","volume":"9","author":"RM Martins","year":"2013","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"7","key":"pone.0352755.ref016","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"SA Plotkin","year":"2010","journal-title":"Clin Vaccine Immunol"},{"issue":"10","key":"pone.0352755.ref017","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1073\/pnas.1500475112","article-title":"Initial viral load determines the magnitude of the human CD8 T cell response","volume":"112","author":"RS Akondy","year":"2015","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"3","key":"pone.0352755.ref018","doi-asserted-by":"crossref","first-page":"434","DOI":"10.4269\/ajtmh.13-0264","article-title":"Efficacy and duration of immunity after yellow fever vaccination","volume":"89","author":"E Gotuzzo","year":"2013","journal-title":"Am J Trop Med Hyg"},{"issue":"6","key":"pone.0352755.ref019","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1590\/S0034-89102010005000046","article-title":"Yellow fever in Brazil: emergence hypotheses","volume":"44","author":"PF Vasconcelos","year":"2010","journal-title":"Rev Saude Publica"},{"issue":"7","key":"pone.0352755.ref020","first-page":"467","article-title":"PRISMA-ScR","volume":"169","author":"AC Tricco","year":"2018","journal-title":"Ann Intern Med"},{"key":"pone.0352755.ref021","doi-asserted-by":"crossref","DOI":"10.46658\/JBIMES-24-01","volume-title":"JBI Manual for Evidence Synthesis","author":"E Aromataris","year":"2024"},{"key":"pone.0352755.ref022","volume-title":"CDC Yellow Book 2026","author":"Centers for Disease Control and Prevention","year":"2025"},{"issue":"48","key":"pone.0352755.ref023","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1016\/j.vaccine.2008.09.009","article-title":"Adverse event reports following yellow fever vaccination","volume":"26","author":"NP Lindsey","year":"2008","journal-title":"Vaccine"},{"issue":"10269","key":"pone.0352755.ref024","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0140-6736(20)32707-0","article-title":"Public health role for fractional dosage of yellow fever vaccine","volume":"397","author":"JE Staples","year":"2021","journal-title":"Lancet"},{"key":"pone.0352755.ref025","author":"Ministerio de Salud del Per\u00fa","year":"2024"},{"key":"pone.0352755.ref026","author":"Ministerio de Salud de Bolivia","year":"2023"},{"key":"pone.0352755.ref027","author":"Instituto Nacional de Salud","year":"2025"},{"key":"pone.0352755.ref028","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0065-3527(03)60009-6","article-title":"Pathogenesis and pathophysiology of yellow fever","volume":"60","author":"TP Monath","year":"2003","journal-title":"Adv Virus Res"},{"key":"pone.0352755.ref029","first-page":"2192","article-title":"Short-lived immunity after 17DD vaccine","volume":"10","author":"AC Campi-Azevedo","year":"2019","journal-title":"Front Immunol"},{"issue":"48","key":"pone.0352755.ref030","first-page":"5798","article-title":"Risk of viscerotropic disease in elderly","volume":"31","author":"E Rafferty","year":"2013","journal-title":"Vaccine"},{"key":"pone.0352755.ref031","author":"Instituto Nacional de Salud","year":"2024"},{"key":"pone.0352755.ref032","author":"Pan American Health Organization","year":"2024"},{"key":"pone.0352755.ref033","author":"Instituto Nacional de Salud","year":"2013"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0352755","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T17:32:32Z","timestamp":1784050352000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0352755"}},"subtitle":[],"editor":[{"given":"Paulo Lee","family":"Ho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":33,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,14]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0352755","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]}}}